Literature DB >> 11994274

Autocrine human growth hormone inhibits placental transforming growth factor-beta gene transcription to prevent apoptosis and allow cell cycle progression of human mammary carcinoma cells.

Ralph Graichen1, DongXu Liu, Yi Sun, Kok-Onn Lee, Peter E Lobie.   

Abstract

Multiple cellular effects of human growth hormone (hGH) are mediated by an indirect mechanism requiring transcriptional activation of genes encoding protein effector molecules such as insulin-like growth factor-1. Such protein effector molecules then act directly to mediate the cellular functions of hGH. We report here that autocrine hGH production by mammary carcinoma cells specifically results in the transcriptional repression of the p53-regulated placental transforming growth factor-beta (PTGF-beta) gene. Transcriptional repression of the PTGF-beta gene does not require the p53-binding sites in the PTGF-beta promoter, and autocrine hGH also desensitized the response of the PTGF-beta promoter to p53 overexpression. Transcriptional repression of the PTGF-beta gene is accompanied by consequent decreases in its protein product, Smad-mediated transcription, and its cellular effects that include cell cycle arrest and apoptosis. PTGF-beta specifically inhibited the autocrine hGH-stimulated expression of cyclin D1 required for autocrine hGH-stimulated mammary carcinoma cell cycle progression. Thus, one mechanism by which autocrine hGH promotes an increase in mammary carcinoma cell number is by transcriptional repression of protein effector molecules that promote cell cycle arrest and apoptosis. Such transcriptional repression of negative regulatory factors, such as PTGF-beta, may also be requisite for direct stimulation of mammary carcinoma cell mitogenesis by hGH.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11994274     DOI: 10.1074/jbc.M109931200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

1.  The oncogenic potential of autocrine human growth hormone in breast cancer.

Authors:  Michael J Waters; Becky L Conway-Campbell
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-12       Impact factor: 11.205

Review 2.  Cancer.

Authors:  Adda Grimberg
Journal:  Adv Exp Med Biol       Date:  2005       Impact factor: 2.622

Review 3.  Extrapituitary growth hormone.

Authors:  S Harvey
Journal:  Endocrine       Date:  2010-10-23       Impact factor: 3.633

4.  GDF-15: a novel serum marker for metastases in uveal melanoma patients.

Authors:  Daniela Suesskind; Andreas Schatz; Sven Schnichels; Sarah E Coupland; Sarah L Lake; Bernd Wissinger; Karl U Bartz-Schmidt; Sigrid Henke-Fahle
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-09-01       Impact factor: 3.117

5.  Plasma Inflammatory Markers and Risk of Advanced Colorectal Adenoma in Women.

Authors:  Mingyang Song; Raaj S Mehta; Kana Wu; Charles S Fuchs; Shuji Ogino; Edward L Giovannucci; Andrew T Chan
Journal:  Cancer Prev Res (Phila)       Date:  2015-10-28

6.  The H6D variant of NAG-1/GDF15 inhibits prostate xenograft growth in vivo.

Authors:  Xingya Wang; Kali Chrysovergis; Rachelle J Bienstock; Minsub Shim; Thomas E Eling
Journal:  Prostate       Date:  2011-08-01       Impact factor: 4.104

7.  Growth hormone promotes lymphangiogenesis.

Authors:  Nadja Erika Banziger-Tobler; Cornelia Halin; Kentaro Kajiya; Michael Detmar
Journal:  Am J Pathol       Date:  2008-06-26       Impact factor: 4.307

Review 8.  The contribution of growth hormone to mammary neoplasia.

Authors:  Jo K Perry; Kumarasamypet M Mohankumar; B Starling Emerald; Hichem C Mertani; Peter E Lobie
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-02-07       Impact factor: 2.673

9.  The Pbx interaction motif of Hoxa1 is essential for its oncogenic activity.

Authors:  Stéphanie Delval; Arnaud Taminiau; Juliette Lamy; Cécile Lallemand; Christine Gilles; Agnès Noël; René Rezsohazy
Journal:  PLoS One       Date:  2011-09-21       Impact factor: 3.240

10.  Tamoxifen-induced epigenetic silencing of oestrogen-regulated genes in anti-hormone resistant breast cancer.

Authors:  Andrew Stone; Fatima Valdés-Mora; Julia M W Gee; Lynne Farrow; Richard A McClelland; Heidi Fiegl; Carol Dutkowski; Rachael A McCloy; Robert L Sutherland; Elizabeth A Musgrove; Robert I Nicholson
Journal:  PLoS One       Date:  2012-07-10       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.